Literature DB >> 26349392

Nanoparticle-Assisted Combinatorial Therapy for Effective Treatment of Endometriosis.

Abhay Kumar Singh, Baidyanath Chakravarty, Koel Chaudhury.   

Abstract

Endometriosis is characterized by the presence of endometrial glands and stroma outside the uterine cavity. Conventional treatment modalities for endometriosis are unsatisfactory; therefore, there is a need to treat the underlying causes and mechanism. Oxidative stress, extracellular matrix degradation, and angiogenesis are associated with the pathogenesis of endometriosis. The anti-angiogenic and antioxidant properties of epigallocatechin gallate and the matrix metalloproteinase inhibitory activity of the antibiotic doxycycline are well established. However, epigallocatechin gallate and doxycycline have several limitations when used in their native forms. This motivated us to synthesize dual drug-loaded (epigallocatechin gallate and doxycycline) nanoparticles and check their therapeutic efficacy in mice with induced endometriosis. The synthesized nanoparticles displayed features of a promising drug-delivery system, such as small size, high encapsulation efficiency, controlled drug release, and low toxicity. The serum of endometriosis-induced mice and controls was assessed for various oxidative stress markers, matrix-degrading enzymes, and angiogenic markers before and after nanoparticle administration. Endometrial glands, stroma, and new microvessels were determined using histochemistry and immunohistochemistry. Treatment with dual drug-loaded nanoparticles markedly decreased oxidative stress, matrix metalloproteinase activity, and angiogenesis, as well as endometrial gland presence and microvessel density. Mitigation of endometriosis-related adverse effects further produced an improvement in the quality of oocytes, which is critical for successful pregnancy outcomes. Our observations suggest that owing to their combinatorial effect, poly(lactic-co-glycolic) acid nanoparticles loaded with epigallocatechin gallate and doxycycline in a single vehicle appear to be promising for the treatment of endometriosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26349392     DOI: 10.1166/jbn.2015.2020

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  7 in total

Review 1.  Drug delivery for the treatment of endometriosis and uterine fibroids.

Authors:  David R Friend
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

2.  Encapsulation of epigallocatechin-3-gallate into albumin nanoparticles improves pharmacokinetic and bioavailability in rat model.

Authors:  Nithya Ramesh; Abul Kalam Azad Mandal
Journal:  3 Biotech       Date:  2019-05-28       Impact factor: 2.406

Review 3.  Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.

Authors:  Abraham S Moses; Ananiya A Demessie; Olena Taratula; Tetiana Korzun; Ov D Slayden; Oleh Taratula
Journal:  Small       Date:  2021-01-25       Impact factor: 13.281

Review 4.  Polyphenols as a Diet Therapy Concept for Endometriosis-Current Opinion and Future Perspectives.

Authors:  Agata Gołąbek; Katarzyna Kowalska; Anna Olejnik
Journal:  Nutrients       Date:  2021-04-18       Impact factor: 5.717

Review 5.  Modulation of Bovine Endometrial Cell Receptors and Signaling Pathways as a Nanotherapeutic Exploration against Dairy Cow Postpartum Endometritis.

Authors:  Ayodele Olaolu Oladejo; Yajuan Li; Xiaohu Wu; Bereket Habte Imam; Jie Yang; Xiaoyu Ma; Zuoting Yan; Shengyi Wang
Journal:  Animals (Basel)       Date:  2021-05-23       Impact factor: 2.752

6.  The Potential of Nanotechnology in Medically Assisted Reproduction.

Authors:  Mariana H Remião; Natalia V Segatto; Adriana Pohlmann; Silvia S Guterres; Fabiana K Seixas; Tiago Collares
Journal:  Front Pharmacol       Date:  2018-01-11       Impact factor: 5.810

Review 7.  Nanotechnology and Reproductive Management of Farm Animals: Challenges and Advances.

Authors:  Nesrein M Hashem; Antonio Gonzalez-Bulnes
Journal:  Animals (Basel)       Date:  2021-06-29       Impact factor: 2.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.